Latest revenue
$0
as of 2026-03-31
Latest net income
$-7.6M
as of 2026-03-31
Net margin
—
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think APTOF is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for APTOF.
5-year trend
What this company does
Item 1. Business Overview Aptose is a science-driven clinical stage biotechnology company dedicated to developing and commercializing precision medicines that address unmet clinical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to deliver single-agent efficacy and to boost the effectiveness of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s executive offices are located in San Diego, California, and its head office is based in Toronto, Canada. Proposed Plan of Arrangement On November 18, 2025, the Company entered into a definitive arrangement agreement (the…
AI summary unavailable — showing raw filing excerpt
Generated from APTOF's filing dated 2026-03-31
Key risks
ITEM 1A. RISK FACTORS Risk Factors and Uncertainties Any of the risks and uncertainties described below could significantly and negatively affect our business, prospects, financial condition, operating results, or credit ratings, which could cause the trading price of our Common Shares to decline. Additional risks and uncertainties not presently known to us, or risks that we currently consider immaterial, could also impair our business operations or financial condition. The following discussion of risk factors contains “forward-looking” statements, as discussed above. Risks Related to the Plan of Arrangement There is no assurance when or if the Arrangement will be completed. The completion…
AI summary unavailable — showing raw filing excerpt
Generated from APTOF's filing dated 2026-03-31
Profitability
Return on equity
560.6%
36.0%Return on assets
-254.4%
1.3%Leverage
Debt / equity
-3.20×
28.7%Debt / assets
145.4%
13.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $0 | — | $-7.6M | -37.7% | — |
Q4 2025 2025-12-31 | $0 | — | $-7.8M | -389.5% | — |
Q3 2025 2025-09-30 | $0 | — | $-5.1M | +26.3% | — |
Q2 2025 2025-06-30 | $0 | — | $-7.0M | +2.9% | — |
Q1 2025 2025-03-31 | $0 | — | $-5.5M | +42.5% | — |
Q4 2024 2024-12-31 | $0 | — | $-1.6M | — | — |
Q3 2024 2024-09-30 | $0 | — | $-7.0M | +39.3% | — |
Q2 2024 2024-06-30 | $0 | — | $-7.3M | +48.7% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on APTOF — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for APTOF in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns APTOF
Institutional value
$7.0K
Total shares held
4.2K
Distinct holders
3
+0 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Gleason Group, Inc. | 4.2K | $7.0K | +0 (+0.0%) | No change |
| 2 | Farther Finance Advisors, LLC | 10 | $17 | +0 (+0.0%) | No change |
| 3 | CALDWELL SUTTER CAPITAL, INC. | 2 | $3 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once APTOF's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.